US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

GSK plc announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making.